PHP
BLRX

Parkman Healthcare Partners’s BioLineRX BLRX Stock Holding History

Parkman Healthcare Partners’s Portfolio BLRX Stock Details BLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,221
Closed -$267K – 83
2022
Q3 		$267K Buy
7,221
+85
+1% +$4.85K 0.08% 87
2022
Q2 		$365K Buy
7,136
+369
+5% +$20.5K 0.13% 72
2022
Q1 		$463K Sell
6,767
-3,948
-37% -$275K 0.14% 75
2021
Q4 		$874K Buy
10,715
+438
+4% +$45.7K 0.19% 77
2021
Q3 		$1.13M Sell
10,277
-8,074
-44% -$958K 0.29% 63
2021
Q2 		$2.06M Buy
18,351
+7,598
+71% +$893K 0.45% 55
2021
Q1 		$1.2M Buy
10,753
+54
+0.5% +$6.49K 0.28% 71
2020
Q4 		$1.08M Buy
+10,699
New +$935K 0.28% 75

Other funds holding BLRX

ACM
Altium Capital Management New York $42M AUM
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.31B AUM 18.36% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Parkman Healthcare Partners's BLRX Position: Q4 2022 in Review

Parkman Healthcare Partners sold out of BioLineRX (BLRX) in Q4 2022, closing a stake of 7,221 shares — an estimated $267K sold.

Parkman Healthcare Partners first reported a position in BLRX in Q4 2020 and held it in 8 quarters. The position peaked at $2.06M in Q2 2021. 18 funds tracked by Wall St. Rank hold BLRX as of Q4 2022.

  • Parkman Healthcare Partners reported no remaining BioLineRX position as of Q4 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 7,221 BioLineRX shares in Q4 2022, an estimated $267K.
  • Parkman Healthcare Partners first reported a position in BioLineRX in Q4 2020 and held it in 8 quarters.
  • Parkman Healthcare Partners's BioLineRX position peaked at $2.06M in Q2 2021.
  • 18 funds tracked by Wall St. Rank held BioLineRX as of Q4 2022.

Based on Parkman Healthcare Partners's 13F filing for Q4 2022, filed 13 Feb 2023.